These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 33278181

  • 21. Implementation of a Novel Adherence Monitoring Strategy in a Phase III, Blinded, Placebo-Controlled, HIV-1 Prevention Clinical Trial.
    Husnik MJ, Brown ER, Marzinke M, Livant E, Palanee-Phillips T, Hendrix CW, Matovu Kiweewa F, Nair G, Soto-Torres LE, Schwartz K, Hillier SL, Baeten JM, MTN-020 ASPIRE Study Team.
    J Acquir Immune Defic Syndr; 2017 Nov 01; 76(3):330-337. PubMed ID: 28746164
    [Abstract] [Full Text] [Related]

  • 22. Impact of Partner-Related Social Harms on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III Trial.
    Palanee-Phillips T, Roberts ST, Reddy K, Govender V, Naidoo L, Siva S, Gafoor Z, Pather A, Matovu F, Hlahla K, Makanani B, Nair G, Schwartz K, Torjesen K, Brown E, Soto-Torres L, Baeten J, Montgomery ET.
    J Acquir Immune Defic Syndr; 2018 Dec 15; 79(5):580-589. PubMed ID: 30239426
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Acceptability and use of a dapivirine vaginal ring in a phase III trial.
    Montgomery ET, van der Straten A, Chitukuta M, Reddy K, Woeber K, Atujuna M, Bekker LG, Etima J, Nakyanzi T, Mayo AJ, Katz A, Laborde N, Grossman CI, Soto-Torres L, Palanee-Phillips T, Baeten JM, MTN-020/ASPIRE Study.
    AIDS; 2017 May 15; 31(8):1159-1167. PubMed ID: 28441175
    [Abstract] [Full Text] [Related]

  • 26. Pharmacokinetics of Dapivirine Transfer into Blood Plasma, Breast Milk, and Cervicovaginal Fluid of Lactating Women Using the Dapivirine Vaginal Ring.
    Noguchi LM, Hoesley C, Kelly C, Scheckter R, Bunge K, Nel A, Marzinke MA, Hendrix CW, Dezzutti CS, Hillier SL, Bogen DL, Piper JM, Beigi RH.
    Antimicrob Agents Chemother; 2019 Mar 15; 63(3):. PubMed ID: 30602513
    [Abstract] [Full Text] [Related]

  • 27. The Influence of Perceived Dapivirine Vaginal Ring Effectiveness on Social Disclosure and Ring Adherence.
    Stoner MCD, Brown ER, Palanee-Phillips T, Mansoor LE, Tembo T, Nair G, Akello C, Seyama L, Jeenarain N, Naidoo L, Mgodi N, Hunidzarira P, Chitukuta M, van der Straten A, MTN-020 ASPIRE and M-025 HOPE study teams.
    AIDS Behav; 2021 Dec 15; 25(12):4169-4179. PubMed ID: 33939034
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention.
    Reidy M, Gardiner E, Pretorius C, Glaubius R, Torjesen K, Kripke K.
    PLoS One; 2019 Dec 15; 14(6):e0218710. PubMed ID: 31242240
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Brief Report: Anal Intercourse, HIV-1 Risk, and Efficacy in a Trial of a Dapivirine Vaginal Ring for HIV-1 Prevention.
    Peebles K, van der Straten A, Palanee-Phillips T, Reddy K, Hillier SL, Hendrix CW, Harkoo I, Gati Mirembe B, Jeenarain N, Baeten JM, Brown ER, MTN-020/ASPIRE Study Team.
    J Acquir Immune Defic Syndr; 2020 Mar 01; 83(3):197-201. PubMed ID: 31809308
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Pregnancy and Infant Outcomes Among Women Using the Dapivirine Vaginal Ring in Early Pregnancy.
    Makanani B, Balkus JE, Jiao Y, Noguchi LM, Palanee-Phillips T, Mbilizi Y, Moodley J, Kintu K, Reddy K, Kabwigu S, Jeenariain N, Harkoo I, Mgodi N, Piper J, Rees H, Scheckter R, Beigi R, Baeten JM.
    J Acquir Immune Defic Syndr; 2018 Dec 15; 79(5):566-572. PubMed ID: 30383589
    [Abstract] [Full Text] [Related]

  • 36. The relationship between vaginal ring use and intimate partner violence and social harms: formative research outcomes from the CHARISMA study in Johannesburg, South Africa.
    Hartmann M, Palanee-Phillips T, O'Rourke S, Adewumi K, Tenza S, Mathebula F, Wagner D, Ayub A, Montgomery ET.
    AIDS Care; 2019 Jun 15; 31(6):660-666. PubMed ID: 30309246
    [Abstract] [Full Text] [Related]

  • 37. Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness.
    Glaubius R, Ding Y, Penrose KJ, Hood G, Engquist E, Mellors JW, Parikh UM, Abbas UL.
    J Int AIDS Soc; 2019 May 15; 22(5):e25282. PubMed ID: 31074936
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Correlates of Adherence to the Dapivirine Vaginal Ring for HIV-1 Prevention.
    Husnik MJ, Brown ER, Dadabhai SS, Gaffoor Z, Jeenarain N, Kiweewa FM, Livant E, Mansoor LE, Mirembe BG, Palanee-Phillips T, Singh D, Siva S, Soto-Torres L, van der Straten A, Baeten JM, M. T. N.-020/ASPIRE Study Team.
    AIDS Behav; 2021 Sep 15; 25(9):2801-2814. PubMed ID: 34117592
    [Abstract] [Full Text] [Related]

  • 40. Misreporting of Product Adherence in the MTN-003/VOICE Trial for HIV Prevention in Africa: Participants' Explanations for Dishonesty.
    Montgomery ET, Mensch B, Musara P, Hartmann M, Woeber K, Etima J, van der Straten A.
    AIDS Behav; 2017 Feb 15; 21(2):481-491. PubMed ID: 27858268
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.